"source","date","assertionType","evidenceType","exactText","modality","statementType","drug1Lab","drug1Type","drug1Role","dose1","drug2Lab","drug2Type","drug2Role","dose2","objectRegimens","objectFormulation","objectDuration","preciptRegimens","preciptFormulation","preciptDuration","numOfParticipants","auc","aucType","aucDirection","cl","clType","clDirection","cmax","cmaxType","cmaxDirection","t12","t12Type","t12Direction"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1a5a93be-7bc3-4714-9308-2fbfb8260e23.html","2016-02-29 15:03:48 -0700","drug-drug-interaction","evidence-supports","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.","ncit:positive","ncit:Qualitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36365",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:01:39 -0800","DDI-clinical-trial","evidence-supports","When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. ","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","triazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",".25","SD","Oral","1","BID","Oral","UNK","UNK","4","Fold","Increase","UNK","UNK","UNK","1.7","Fold","Increase","4","Fold","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 14:35:23 -0700","DDI-clinical-trial","evidence-supports","Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.","ncit:positive","ncit:quantitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","iloperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","3","SD","Oral","1","BID","Oral","4","19","57","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d78e9639-6fab-4a78-8b29-6991a18ae6c6.html","2016-02-19 17:46:51 -0500","drug-drug-interaction","evidence-supports","In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events.    The concomitant administration of other drugs that inhibit the activity of P450 2D6 may acutely increase plasma concentrations of antipsychotics. Among these are tricyclic antidepressants and selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline and paroxetine. When prescribing these drugs to patients already receiving antipsychotic therapy, close monitoring is essential and dose reduction may become necessary to avoid toxicity. Lower doses than usually prescribed for either the antipsychotic or the other drug may be required.","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"perphenazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35375",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:37:32 -0700","DDI-clinical-trial","evidence-supports","The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered.","ncit:positive","ncit:quantitative","sulforidazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","UNK","Fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","UNK","Oral","UNK","BID","Oral","7","10","3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 15:12:19 -0700","DDI-clinical-trial","evidence-supports","Dextromethorphan: A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in the maximum plasma concentrations (Cmax)of dextromethorphan. Thus, an interaction between iloperidone and other CYP2D6 substrates is unlikely.","ncit:positive","ncit:quantitative","dextromethorphan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","80","iloperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","3","SD","Oral","1","SD","Oral","1","UNK","17","Percent","Increase","UNK","UNK","UNK","26","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:37:19 -0800","DDI-clinical-trial","evidence-challenges","Phenytoin – Pretreatment for 7 days with 200 mg BID of nefazodone had no effect on the pharmacokinetics of a single 300 mg oral dose of phenytoin. However, due to the nonlinear pharmacokinetics of phenytoin, the failure to observe a significant effect on the single-dose pharmacokinetics of phenytoin does not preclude the possibility of a clinically significant interaction with nefazodone when phenytoin is dosed chronically. ","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","Phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","300","SD","Oral","1","BID","Oral","7","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-02-18 16:49:30 -0700","DDI-clinical-trial","evidence-supports","A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about 3-fold compared to baseline steady-state concentrations.","ncit:positive","ncit:quantitative","clozapine N-oxide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","UNK","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","14","16","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:29:38 -0800","DDI-clinical-trial","evidence-challenges","Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.","ncit:negative","ncit:quantitative","Lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","5","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","SD","Oral","1","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:34:55 -0700","drug-drug-interaction","evidence-supports","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)","ncit:positive","ncit:Qualitative","indinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36222",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:52:49 -0700","DDI-clinical-trial","evidence-challenges","Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Drug Interactions (7.4)].","ncit:negative","ncit:quantitative","salicylic acid","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","150","BRINTELLIX","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","Daily","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNKUNUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2015-12-08 19:35:35 -0700","DDI-clinical-trial","evidence-challenges","Valproate: It is not necessary to adjust the LATUDA dose when used concomitantly with valproate. A dedicated drug-drug interaction study has not been conducted with valproate and LATUDA. Based on pharmacokinetic data from the bipolar depression studies valproate levels were not affected by lurasidone, and lurasidone concentrations were not affected by valproate. ","ncit:negative","ncit:quantitative","lurasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:11:00 -0800","DDI-clinical-trial","evidence-supports","When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold.","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1","BID","Oral","UNK","BID","Oral","UNK","UNK","2","Fold","Increase","UNK","UNK","UNK","2","Fold","Increase","2","Fold","Increase"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1a5a93be-7bc3-4714-9308-2fbfb8260e23.html","2016-02-29 17:07:32 -0500","drug-drug-interaction","evidence-supports","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.","ncit:positive","ncit:Qualitative","phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35093",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:19:31 -0700","drug-drug-interaction","evidence-supports","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.","ncit:positive","ncit:Qualitative","thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35888","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:04:35 -0800","DDI-clinical-trial","evidence-supports","With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%).","ncit:positive","ncit:quantitative","buspirone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","hydroxynefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","250","BID","Oral","UNK","BID","Oral","UNK","UNK","17","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:37:29 -0700","drug-drug-interaction","evidence-supports","Concomitant use of CLOZARIL and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the CLOZARIL dose to one-third of the original dose when CLOZARIL is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The CLOZARIL dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b34306","ciprofloxacin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 13:28:51 -0700","DDI-clinical-trial","evidence-challenges","Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine.","ncit:negative","ncit:quantitative","imipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 12:34:19 -0700","DDI-clinical-trial","evidence-supports"," Carbamazepine therapy (200 mg bid) causes an approximately 50% increase in the clearance of olanzapine. ","ncit:positive","ncit:quantitative","Carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","50","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 13:30:19 -0700","DDI-clinical-trial","evidence-challenges","Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine.","ncit:negative","ncit:quantitative","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","SD","Oral","1","UNK","UNKUNUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:26:49 -0800","DDI-clinical-trial","evidence-challenges"," Pharmacodynamic effects of haloperidol were generally not altered significantly. There were no changes in the pharmacokinetic parameters for nefazodone","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","haloperidol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","BID","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 12:20:54 -0800","drug-drug-interaction","evidence-supports","There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. Both cyclosporine and tacrolimus are substrates of CYP3A4, and nefazodone is known to inhibit this enzyme. If either cyclosporine or tacrolimus is administered with nefazodone, blood concentrations of the immunosuppressive agent should be monitored and dosage adjusted accordingly.","ncit:positive","ncit:Qualitative","cyclosporine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36613","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 12:14:12 -0800","drug-drug-interaction","evidence-supports","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","ncit:positive","ncit:Qualitative","mCPP","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","nodeID://b33454","Lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html","2015-11-29 18:49:20 -0500","DDI-clinical-trial","evidence-challenges","Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. Dose adjustment for digoxin is not recommended.","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",".25","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 12:58:57 -0800","DDI-clinical-trial","evidence-supports","Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone","ncit:positive","ncit:quantitative","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:29:38 -0800","DDI-clinical-trial","evidence-challenges"," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively","ncit:negative","ncit:quantitative","HO-NEF","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","200","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). and decreased by the prototype CYP3A4 inducers (e..g, phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.).","ncit:positive","ncit:Qualitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36259",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:52:09 -0700","DDI-clinical-trial","evidence-challenges","Ziprasidone at a dose of 40 mg twice daily administered concomitantly with lithium at a dose of 450 mg twice daily for 7 days did not affect the steady-state level or renal clearance of lithium. Ziprasidone dosed adjunctively to lithium in a maintenance trial of bipolar patients did not affect mean therapeutic lithium levels.","ncit:negative","ncit:quantitative","Ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","450","BID","Oral","7","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 12:22:19 -0800","drug-drug-interaction","evidence-supports","There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. Both cyclosporine and tacrolimus are substrates of CYP3A4, and nefazodone is known to inhibit this enzyme. If either cyclosporine or tacrolimus is administered with nefazodone, blood concentrations of the immunosuppressive agent should be monitored and dosage adjusted accordingly.","ncit:positive","ncit:Qualitative","tacrolimus","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36470","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:34:30 -0700","drug-drug-interaction","evidence-supports","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)","ncit:positive","ncit:Qualitative","itraconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b31719",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). and decreased by the prototype CYP3A4 inducers (e..g, phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.).","ncit:positive","ncit:Qualitative","Quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36626","avasimibe","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:43:26 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","ncit:positive","ncit:Qualitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36400",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:41:56 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","ncit:positive","ncit:Qualitative","clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35878","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:50:39 -0700","drug-drug-interaction","evidence-supports","Coadministration of ketoconazole, a potent inhibitor of cytochrome CYP3A4, resulted in significant increase in quetiapine exposure.","ncit:positive","ncit:Qualitative","quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36167","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:47:05 -0800","DDI-clinical-trial","evidence-challenges","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.","ncit:negative","ncit:quantitative","hydroxynefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","200","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","BID","Oral","5.5","BID","Oral","5.5","18","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:33:34 -0800","DDI-clinical-trial","evidence-supports"," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively","ncit:positive","ncit:quantitative","mCPP","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","200","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","QD","Oral","UNK","UNK","3 to 6","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a971ea18-40cf-4a01-b696-180ccc3fddb5.html","2016-02-29 14:04:47 -0700","drug-drug-interaction","evidence-supports","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.","ncit:positive","ncit:Qualitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36277",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 12:34:19 -0700","DDI-clinical-trial","evidence-supports","Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance of olanzapine. This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers. The mean increase in olanzapine AUC is 52% and 108%, respectively.","ncit:positive","ncit:quantitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","52-108","Percent","Increase","UNK","UNK","UNK","54 - 77\\\\n54-77","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:36:22 -0700","DDI-clinical-trial","evidence-challenges","No clinically relevant effect was observed on steady state lithium exposure following coadministration with multiple daily doses of BRINTELLIX.","ncit:negative","ncit:quantitative","lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","BRINTELLIX","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a971ea18-40cf-4a01-b696-180ccc3fddb5.html","2016-02-29 16:08:19 -0500","drug-drug-interaction","evidence-supports","Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Dilantin®‡ (phenytoin) and thus precipitate Dilantin (phenytoin) toxicity.","ncit:positive","ncit:Qualitative","Dilantin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35153","Phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 12:06:08 -0800","DDI-clinical-trial","evidence-supports","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","atorvastatin lactone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","40","SD","Oral","1","BID","Oral","6","UNK","3 to 4","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:42:44 -0800","DDI-clinical-trial","evidence-challenges","There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","150","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","BID","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:44:17 -0700","DDI-clinical-trial","evidence-challenges","Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Drug Interactions (7.4)].","ncit:negative","ncit:quantitative","BRINTELLIX","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","aspirin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","150","Daily","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5429f134-839f-4ffc-9944-55f51238def8.html","2015-12-18 15:57:58 -0500","DDI-clinical-trial","evidence-supports","Coadministration of paroxetine with SAPHRIS caused a two-fold increase in the maximum plasma concentrations and    systemic exposure of paroxetine. Asenapine enhances the inhibitory effects of paroxetine on its own metabolism by CYP2D6.","ncit:positive","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","SAPHRIS","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","2","Fold","Increase","UNK","UNK","UNK","2","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:44:04 -0800","DDI-clinical-trial","evidence-challenges","There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","ncit:negative","ncit:quantitative","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","triazole-dione","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","150","BID","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNKUNUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 14:46:00 -0700","DDI-clinical-trial","evidence-supports","Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. ","ncit:positive","ncit:quantitative","P88","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","3","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","SD","Oral","1","BID","Oral","21","23","2 to 3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:43:01 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","ncit:positive","ncit:Qualitative","clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36552","terbinafine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d78e9639-6fab-4a78-8b29-6991a18ae6c6.html","2016-02-19 17:46:51 -0500","drug-drug-interaction","evidence-supports","In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events.    The concomitant administration of other drugs that inhibit the activity of P450 2D6 may acutely increase plasma concentrations of antipsychotics. Among these are tricyclic antidepressants and selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline and paroxetine. When prescribing these drugs to patients already receiving antipsychotic therapy, close monitoring is essential and dose reduction may become necessary to avoid toxicity. Lower doses than usually prescribed for either the antipsychotic or the other drug may be required.","ncit:positive","ncit:Qualitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"perphenazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b34590",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html","2015-11-29 16:36:20 -0700","DDI-clinical-trial","evidence-challenges","Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. Dose adjustment for valproate is not recommended.","ncit:negative","ncit:quantitative","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1000","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","4","Daily","Oral","UNK","QD","Oral","UNK","21","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:51:32 -0800","DDI-clinical-trial","evidence-supports","Buspirone – In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine. ","ncit:positive","ncit:quantitative","buspirone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","2.5 or 5","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","250","BID","Oral","UNK","BID","Oral","UNK","UNK","up to 50","Fold","Increase","UNK","UNK","UNK","up to 20","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 12:56:43 -0800","DDI-clinical-trial","evidence-supports","Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone.","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","triazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 12:05:05 -0800","drug-drug-interaction","evidence-supports","The coadministration of triazolam and nefazodone causes a significant increase in the plasma level of triazolam (see WARNINGS and PRECAUTIONS), and a 75% reduction in the initial triazolam dosage is recommended if the two drugs are to be given together. ","ncit:positive","ncit:Qualitative","triazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b29160","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2016-02-18 18:45:32 -0500","DDI-clinical-trial","evidence-supports","Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. ","ncit:positive","ncit:quantitative","P88","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","8 or 12","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","Daily","Oral","5 to 8","UNK","UNK","UNK","UNK","UNK","UNK","UNK","1.6","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 16:22:18 -0700","DDI-clinical-trial","evidence-challenges"," Olanzapine did not influence the pharmacokinetics of diazepam or its active metabolite N-desmethyldiazepam.","ncit:negative","ncit:quantitative","Olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:51:40 -0800","DDI-clinical-trial","evidence-challenges","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","ncit:negative","ncit:quantitative","Lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","500","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","BID","Oral","5","BID","Oral","5","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:51:10 -0800","DDI-clinical-trial","evidence-supports","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.","ncit:positive","ncit:quantitative","m-chlorophenylpiperazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","200","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","BID","Oral","5.5","BID","Oral","5.5","18","28","Percent","Increase","UNK","UNK","UNK","23","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:59:13 -0700","DDI-clinical-trial","evidence-challenges","Consistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.","ncit:negative","ncit:quantitative","dextrorphan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 15:59:31 -0500","DDI-clinical-trial","evidence-challenges","Because vortioxetine is highly bound to plasma protein, coadministration of BRINTELLIX with another drug that is highly protein bound may increase free concentrations of the other drug. However, in a clinical study with coadministration of BRINTELLIX (10 mg/day) and warfarin (1 mg/day to 10 mg/day), a highly protein-bound drug, no significant change in INR was observed [see Drug Interactions (7.2)].","ncit:negative","ncit:quantitative","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1 to 10","BRINTELLIX","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","Daily","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-02-18 18:51:21 -0500","DDI-clinical-trial","evidence-supports","A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about 3-fold compared to baseline steady-state concentrations","ncit:positive","ncit:quantitative","clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","14","16","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html","2015-11-29 16:18:02 -0700","DDI-clinical-trial","evidence-supports","Co-administration of INVEGA® 6 mg once daily with carbamazepine, a strong inducer of both CYP3A4 and P-glycoprotein (P-gp), at 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration.","ncit:positive","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","INVEGA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","6","QD","Oral","UNK","BID","Oral","UNK","UNK","37","Percent","Decrease","35","Percent","Increase","37","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:40:46 -0800","DDI-clinical-trial","evidence-challenges","Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. ","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","150","Desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","75","QD","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:38:00 -0700","DDI-clinical-trial","evidence-challenges","Multiple doses of BRINTELLIX did not affect the pharmacokinetics or pharmacodynamics (composite cognitive score) of diazepam.","ncit:negative","ncit:quantitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","BRINTELLIX","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:03:19 -0800","DDI-clinical-trial","evidence-challenges","Nefazodone plasma concentrations were unaffected by triazolam.","ncit:negative","ncit:quantitative","Nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","triazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",".25","BID","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 19:04:34 -0700","DDI-clinical-trial","evidence-challenges","Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.         The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food","ncit:negative","ncit:quantitative","benztropine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:05:41 -0800","DDI-clinical-trial","evidence-challenges","When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered for one week, no change in the steady-state pharmacokinetics of either nefazodone or cimetidine was observed compared to each dosed alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.","ncit:negative","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","300","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","QID","Oral","7","BID","Oral","7","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html","2015-11-29 16:36:20 -0700","DDI-clinical-trial","evidence-challenges","Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (n=13). Dose adjustment for lithium is not recommended.","ncit:negative","ncit:quantitative","lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","3","UNK","Oral","UNK","BID","Oral","UNK","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 12:37:44 -0700","DDI-clinical-trial","evidence-supports","Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance","ncit:positive","ncit:quantitative","Fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","60","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","QD","Oral","8","UNK","UNKUNK","UNK","UNK","16","Percent","Decrease","16","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:57:09 -0800","DDI-clinical-trial","evidence-supports","Buspirone – In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of buspirone (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma buspirone concentrations (increases up to 20 fold in Cmax and up to 50 fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the buspirone metabolite 1-pyrimidinylpiperazine.","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","250","1-pyrimidinylpiperazine.","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","2.5 or 5","BID","Oral","UNK","BID","Oral","UNK","UNK","about 50","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:24:30 -0800","DDI-clinical-trial","evidence-challenges"," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine.","ncit:negative","ncit:quantitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","20","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","QD","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 16:22:18 -0700","DDI-clinical-trial","evidence-challenges","Single doses of olanzapine did not affect the pharmacokinetics of warfarin ","ncit:negative","ncit:quantitative","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:20:40 -0700","drug-drug-interaction","evidence-supports","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.","ncit:positive","ncit:Qualitative","thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36609","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:38:01 -0700","drug-drug-interaction","evidence-supports","Concomitant use of CLOZARIL and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the CLOZARIL dose to one-third of the original dose when CLOZARIL is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The CLOZARIL dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","enoxacin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35786",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:52:49 -0700","DDI-clinical-trial","evidence-challenges","Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2).","ncit:negative","ncit:quantitative","bupropion","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","BRINTELLIX","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:36:49 -0700","drug-drug-interaction","evidence-supports","oncomitant use of CLOZARIL and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the CLOZARIL dose to one-third of the original dose when CLOZARIL is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The CLOZARIL dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b32838","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:33:28 -0800","DDI-clinical-trial","evidence-challenges","Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","Lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","2","BID","Oral","UNK","BID","Oral","UNK","UNK","UNKUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 19:05:25 -0700","DDI-clinical-trial","evidence-challenges","Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.         The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food","ncit:negative","ncit:quantitative","ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 14:55:02 -0700","DDI-clinical-trial","evidence-supports","Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. ","ncit:positive","ncit:quantitative","P95","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","8 or 12","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","Daily","Oral","5 to 8","UNK","UNK","UNK","UNK","UNK","UNK","UNK","50","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:01:56 -0800","DDI-clinical-trial","evidence-supports","With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%).","ncit:positive","ncit:quantitative","buspirone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","250","BID","Oral","UNK","BID","Oral","UNK","UNK","23","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 14:46:00 -0700","DDI-clinical-trial","evidence-supports","Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. ","ncit:positive","ncit:quantitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","iloperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","3","SD","Oral","1","BID","Oral","21","23","2 to 3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 12:34:19 -0700","drug-drug-interaction","evidence-challenges","Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine. ","ncit:negative","ncit:Qualitative","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b31422","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 18:57:43 -0500","DDI-clinical-trial","evidence-supports","Coadministration of quetiapine and phenytoin, a CYP3A4 inducer increased the mean oral clearance of quetiapine by 5-fold.","ncit:positive","ncit:quantitative","quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","5","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:57:37 -0700","DDI-clinical-trial","evidence-challenges","Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2).","ncit:negative","ncit:quantitative","BRINTELLIX","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:57:37 -0700","DDI-clinical-trial","evidence-challenges","Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2)","ncit:negative","ncit:quantitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","BRINTELLIX","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:40:02 -0700","drug-drug-interaction","evidence-supports","Concurrent administration of propranolol (100 to 800 mg daily) has been reported to produce increases in plasma levels of thioridazine (approximately 50% to 400%) and its metabolites (approximately 80% to 300%). Propranolol and thioridazine should not be coadministered.","ncit:positive","ncit:Qualitative","thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36147","Propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). and decreased by the prototype CYP3A4 inducers (e..g, phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.).","ncit:positive","ncit:Qualitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b33013",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:52:47 -0800","DDI-clinical-trial","evidence-challenges","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","ncit:negative","ncit:quantitative","HO-NEF","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","200","Lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","500","BID","Oral","5","BID","Oral","5","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:27:03 -0800","DDI-clinical-trial","evidence-challenges","When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively.","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","QD","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 12:04:34 -0800","DDI-clinical-trial","evidence-supports","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","40","SD","Oral","1","BID","Oral","6","UNK","3 to 4","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:11:14 -0800","DDI-clinical-trial","evidence-challenges","When nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","600 to 1200","BID","Oral","UNK","Daily","Oral","UNK","UNK","UNK","UNK","UNK","UNKUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:37:36 -0800","DDI-clinical-trial","evidence-supports","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol.","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","40","BID","Oral","5.5","BID","Oral","5.5","18","14","Percent","Decrease","UNK","UNK","UNK","30","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 12:04:34 -0800","DDI-clinical-trial","evidence-supports","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent","ncit:positive","ncit:quantitative","simvastatin acid","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","200","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","BID","Oral","6","SD","Oral","1","UNK","20","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:39:55 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)].","ncit:positive","ncit:Qualitative","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35162",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:43:01 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","ncit:positive","ncit:Qualitative","clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b34387","duloxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:07:38 -0800","DDI-clinical-trial","evidence-supports","With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%)","ncit:positive","ncit:quantitative","mCPP","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","250","buspirone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","BID","Oral","UNK","BID","Oral","UNK","UNK","9","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:24:14 -0800","DDI-clinical-trial","evidence-supports","Haloperidol – When a single oral 5 mg dose of haloperidol was coadministered with nefazodone (200 mg BID) at steady state, haloperidol apparent clearance decreased by 35% with no significant increase in peak haloperidol plasma concentrations or time of peak.","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","haloperidol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","5","SD","Oral","1","BID","Oral","UNK","UNK","UNK","UNK","UNK","35","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4b0700c9-b417-4c3a-b36f-de461e125bd3.html","2015-11-29 13:42:04 -0700","DDI-clinical-trial","evidence-challenges","Following coadministration of stable doses of warfarin (1 to 10 mg/day) with multiple daily doses of BRINTELLIX, no significant effects were observed in INR, prothrombin values or total warfarin (protein bound plus free drug) pharmacokinetics for both R- and S-warfarin [see Drug Interactions (7.4)].","ncit:negative","ncit:quantitative","BRINTELLIX","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1 to 10","Daily","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:57:19 -0700","DDI-clinical-trial","evidence-challenges","In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. Ziprasidone at a dose of 20 mg twice daily did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg).","ncit:negative","ncit:quantitative","levonorgestrel","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",".15","Ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 16:44:38 -0500","drug-drug-interaction","evidence-supports","Concurrent administration of pindolol and thioridazine have resulted in moderate, dose related increases in the serum levels of thioridazine and two of its metabolites, as well as higher than expected serum pindolol levels. Pindolol and thioridazine should not be coadministered.","ncit:positive","ncit:Qualitative","pindolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b32253","thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:39:55 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]. ","ncit:positive","ncit:Qualitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35794",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5429f134-839f-4ffc-9944-55f51238def8.html","2015-12-18 13:50:52 -0700","DDI-clinical-trial","evidence-supports","SAPHRIS may enhance the inhibitory effects of paroxetine on its own metabolism. Concomitant use of paroxetine with SAPHRIS increased the paroxetine exposure by 2-fold as compared to use paroxetine alone [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:quantitative","SAPHRIS","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","2","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html","2015-11-29 16:14:39 -0700","DDI-clinical-trial","evidence-challenges","In a drug interaction study, co-administration of INVEGA® (12 mg once daily for 5 days) with divalproex sodium extended-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics (AUC24h and Cmax,ss) of valproate in 13 patients stabilized on valproate. ","ncit:negative","ncit:quantitative","divalproex sodium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","500 to 2000","INVEGA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","12","QD","Oral","UNK","QD","Oral","5","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:41:56 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","ncit:positive","ncit:Qualitative","bupropion","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b33387",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 16:24:02 -0700","DDI-clinical-trial","evidence-challenges","Olanzapine did not influence the pharmacokinetics of diazepam or its active metabolite N-desmethyldiazepam.","ncit:negative","ncit:quantitative","N-desmethyldiazepam.","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","UNK","Olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:44:10 -0700","DDI-clinical-trial","evidence-supports","Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. This effect may be greater when higher doses of carbamazepine are administered. ","ncit:positive","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","BID","Oral","21","UNK","35","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:50:07 -0700","DDI-clinical-trial","evidence-challenges","Cimetidine at a dose of 800 mg QD for 2 days did not affect ziprasidone pharmacokinetics.","ncit:negative","ncit:quantitative","ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","800","UNK","Oral","UNK","QD","Oral","2","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2015-12-18 15:38:03 -0700","DDI-clinical-trial","evidence-supports","A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about 3-fold compared to baseline steady-state concentrations.","ncit:positive","ncit:quantitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","N-desmethylclozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","Oral","14","16","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 18:55:35 -0700","DDI-clinical-trial","evidence-challenges","In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. Ziprasidone at a dose of 20 mg twice daily did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg).","ncit:negative","ncit:quantitative","ethinyl estradiol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",".03","ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:46:00 -0800","DDI-clinical-trial","evidence-supports","There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","ncit:positive","ncit:quantitative","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","mCPP","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","150","BID","Oral","UNK","QD","Oral","UNK","UNK","44","Percent","Increase","UNK","UNK","UNK","48","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 12:46:01 -0700","drug-drug-interaction","evidence-supports"," Omeprazole and rifampin may cause an increase in olanzapine clearance. ","ncit:positive","ncit:Qualitative","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35800","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:22:02 -0700","drug-drug-interaction","evidence-supports","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.","ncit:positive","ncit:Qualitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b31339",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5429f134-839f-4ffc-9944-55f51238def8.html","2015-12-18 13:50:52 -0700","DDI-clinical-trial","evidence-supports","SAPHRIS is metabolized by CYP1A2. Marginal increase of asenapine exposure was observed when SAPHRIS is used with fluvoxamine at 25 mg administered twice daily [see Clinical Pharmacology (12.3)","ncit:positive","ncit:quantitative","SAPHRIS","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","UNK","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:09:54 -0800","DDI-clinical-trial","evidence-challenges","When nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.","ncit:negative","ncit:quantitative","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","600 to 1200","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","Daily","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 13:18:12 -0700","DDI-clinical-trial","evidence-challenges","Multiple doses of olanzapine (10 mg for 8 days) did not influence the kinetics of lithium. ","ncit:negative","ncit:quantitative","lithium.","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","UNK","Oral","UNK","UNK","Oral","8","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:23:33 -0800","DDI-clinical-trial","evidence-supports","Digoxin – When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered for 9 days to healthy male volunteers (n = 18) who were phenotyped as CYP2D6 extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by 29%, 27%, and 15%, respectively.","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction",".2","QD","Oral","9","BID","Oral","9","18","15","Percent","Increase","UNK","UNK","UNK","29","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:22:02 -0700","drug-drug-interaction","evidence-supports","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.","ncit:positive","ncit:Qualitative","pindolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35641",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 18:26:57 -0500","DDI-clinical-trial","evidence-challenges","Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites. ","ncit:negative","ncit:quantitative","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:47:05 -0800","DDI-clinical-trial","evidence-challenges","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.","ncit:negative","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","BID","Oral","5.5","BID","Oral","5.5","18","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 12:08:12 -0800","DDI-clinical-trial","evidence-challenges","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent","ncit:negative","ncit:quantitative","pravastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","UNK","Oral","UNK","BID","Oral","6","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html","2015-11-29 16:15:29 -0700","drug-drug-interaction","evidence-challenges","In a clinical study, subjects on stable doses of valproate had comparable valproate average plasma concentrations when INVEGA® 3–15 mg/day was added to their existing valproate treatment.","ncit:negative","ncit:Qualitative","INVEGA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b31168",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a971ea18-40cf-4a01-b696-180ccc3fddb5.html","2016-02-29 16:08:19 -0500","drug-drug-interaction","evidence-supports","Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs","ncit:positive","ncit:Qualitative","phenothiazines","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b32066",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:37:36 -0800","DDI-clinical-trial","evidence-challenges","Digoxin – When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered for 9 days to healthy male volunteers (n = 18) who were phenotyped as CYP2D6 extensive metabolizers, Cmax, Cmin, and AUC of digoxin were increased by 29%, 27%, and 15%, respectively. Digoxin had no effects on the pharmacokinetics of nefazodone and its active metabolites. Because of the narrow therapeutic index of digoxin, caution should be exercised when nefazodone and digoxin are coadministered; plasma level monitoring for digoxin is recommended.","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",".2","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","BID","Oral","9","QD","Oral","9","18","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7b8e5b26-b9e4-4704-921b-3c3c0d159916.html","2015-11-29 18:21:18 -0500","DDI-clinical-trial","evidence-supports","Co-administration of a single dose of INVEGA® 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the Cmax and AUC of paliperidone. Dosage reduction for INVEGA® should be considered when INVEGA® is co-administered with valproate after clinical assessment.","ncit:positive","ncit:quantitative","INVEGA","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","12","divalproex sodium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","1000","SD","Oral","1","QD","Oral","UNK","UNK","50","Percent","Increase","UNK","UNK","UNK","50","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/afad3051-9df2-4c54-9684-e8262a133af8.html","2015-12-08 19:34:38 -0700","DDI-clinical-trial","evidence-challenges","Valproate: It is not necessary to adjust the LATUDA dose when used concomitantly with valproate. A dedicated drug-drug interaction study has not been conducted with valproate and LATUDA. Based on pharmacokinetic data from the bipolar depression studies valproate levels were not affected by lurasidone, and lurasidone concentrations were not affected by valproate. ","ncit:negative","ncit:quantitative","lurasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:39:55 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)].","ncit:positive","ncit:Qualitative","escitalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b30746",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:41:56 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)]","ncit:positive","ncit:Qualitative","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35194",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:07:13 -0800","DDI-clinical-trial","evidence-challenges","When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered for one week, no change in the steady-state pharmacokinetics of either nefazodone or cimetidine was observed compared to each dosed alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","300","BID","Oral","7","QID","Oral","7","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d78e9639-6fab-4a78-8b29-6991a18ae6c6.html","2016-02-19 17:46:51 -0500","drug-drug-interaction","evidence-supports","In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events.    The concomitant administration of other drugs that inhibit the activity of P450 2D6 may acutely increase plasma concentrations of antipsychotics. Among these are tricyclic antidepressants and selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline and paroxetine. When prescribing these drugs to patients already receiving antipsychotic therapy, close monitoring is essential and dose reduction may become necessary to avoid toxicity. Lower doses than usually prescribed for either the antipsychotic or the other drug may be required.","ncit:positive","ncit:Qualitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"perphenazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b29908",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:37:32 -0700","DDI-clinical-trial","evidence-supports","The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered.","ncit:positive","ncit:quantitative","mesoridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","Fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","BID","Oral","7","10","3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 15:19:40 -0700","DDI-clinical-trial","evidence-challenges","luoxetine: A single 3 mg dose of iloperidone had no effect on the pharmacokinetics of fluoxetine (20 mg twice daily). ","ncit:negative","ncit:quantitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","20","iloperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","3","BID","Oral","UNK","SD","Oral","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 13:12:47 -0800","DDI-clinical-trial","evidence-challenges","Nefazodone plasma concentrations were unaffected by alprazolam. ","ncit:negative","ncit:quantitative","Nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","200","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","1","BID","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:24:30 -0800","DDI-clinical-trial","evidence-challenges"," When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine.","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","norfluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","20","QD","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:40:46 -0800","DDI-clinical-trial","evidence-challenges","Desipramine – When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. ","ncit:negative","ncit:quantitative","2-hydroxy desipramine.","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","75","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","150","QD","Oral","UNK","BID","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 16:44:38 -0500","drug-drug-interaction","evidence-supports","Concurrent administration of pindolol and thioridazine have resulted in moderate, dose related increases in the serum levels of thioridazine and two of its metabolites, as well as higher than expected serum pindolol levels. Pindolol and thioridazine should not be coadministered.","ncit:positive","ncit:Qualitative","pindolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36565",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:07:38 -0800","DDI-clinical-trial","evidence-supports","With 5 mg BID doses of buspirone, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%)","ncit:positive","ncit:quantitative","hydroxynefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","250","buspirone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","5","BID","Oral","UNK","BID","Oral","UNK","UNK","17","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 12:46:01 -0700","drug-drug-interaction","evidence-supports"," Omeprazole and rifampin may cause an increase in olanzapine clearance. ","ncit:positive","ncit:Qualitative","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b34815","Omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 12:00:53 -0800","DDI-clinical-trial","evidence-supports","HMG-CoA Reductase Inhibitors – When single 40 mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received nefazodone hydrochloride, 200 mg BID for 6 days, approximately 20 fold increases in plasma concentrations of simvastatin and simvastatin acid and 3 to 4 fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by nefazodone because, in the same study, nefazodone had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent.","ncit:positive","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","simvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","40","QD","Oral","1","BID","Oral","6","UNK","20","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-27 14:35:40 -0800","DDI-clinical-trial","evidence-supports","When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively","ncit:positive","ncit:quantitative","triazole-dione","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","200","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","QD","Oral","UNK","UNK","1.3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:33:50 -0700","drug-drug-interaction","evidence-supports","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)","ncit:positive","ncit:Qualitative","Quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b35859","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:41:53 -0800","DDI-clinical-trial","evidence-supports","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol.","ncit:positive","ncit:quantitative","4-hydroxypropranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","40","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","BID","Oral","5.5","BID","Oral","5.5","18","UNK","UNK","UNK","UNK","UNK","UNK","14","Percent","Decrease","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:47:19 -0800","DDI-clinical-trial","evidence-supports","There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and Cmax of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.","ncit:positive","ncit:quantitative","HO-NEF","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","150","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","75","BID","Oral","UNK","QD","Oral","UNK","UNK","19","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/49c4105b-e518-481c-a248-6684135f5bc1.html","2015-11-29 16:36:20 -0700","DDI-clinical-trial","evidence-supports","Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. Dose adjustment for valproate is not recommended.","ncit:positive","ncit:quantitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","4","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","1000","Daily","Oral","UNK","QD","Oral","UNK","21","UNK","UNK","UNK","UNK","UNK","UNK","20","Percent","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 16:25:17 -0700","DDI-clinical-trial","evidence-challenges","Multiple doses of olanzapine did not influence the kinetics of biperiden. ","ncit:negative","ncit:quantitative","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","biperiden","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:34:13 -0700","DDI-clinical-trial","evidence-supports","The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered.","ncit:positive","ncit:quantitative","thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","25","UNK","Oral","UNK","BID","Oral","7","10","3","Fold","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 19:04:34 -0700","DDI-clinical-trial","evidence-challenges","Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.         The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food","ncit:negative","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f0c6f5f-b906-4c8f-8580-3939a476a1c1.html","2016-01-11 10:40:30 -0700","drug-drug-interaction","evidence-supports","Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the CLOZARIL dose [see Dosage and Administration (2.6)","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b30775",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 12:14:12 -0800","drug-drug-interaction","evidence-supports","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","ncit:positive","ncit:Qualitative","Lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"triazole-dione","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","nodeID://b36566",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/036db1f2-52b3-42a0-acf9-817b7ba8c724.html","2015-12-08 19:00:54 -0700","DDI-clinical-trial","evidence-challenges","A pharmacokinetic interaction of ziprasidone with valproate is unlikely due to the lack of common metabolic pathways for the two drugs. Ziprasidone dosed adjunctively to valproate in a maintenance trial of bipolar patients did not affect mean therapeutic valproate levels.","ncit:negative","ncit:quantitative","ziprasidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","UNK","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","UNK","Oral","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 13:21:48 -0700","DDI-clinical-trial","evidence-challenges","Olanzapine (10 mg daily for 2 weeks) did not affect the steady state plasma concentrations of valproate","ncit:negative","ncit:quantitative","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","Olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","10","UNK","Oral","UNK","QD","Oral","14","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 12:44:17 -0700","drug-drug-interaction","evidence-challenges","Warfarin (20 mg single dose) did not affect olanzapine pharmacokinetics ","ncit:negative","ncit:Qualitative","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36185","Warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 14:49:58 -0700","DDI-clinical-trial","evidence-supports","Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. ","ncit:positive","ncit:quantitative","iloperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","8 or 12","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","BID","Oral","UNK","Daily","Oral","5 to 8","UNK","UNK","UNK","UNK","UNK","UNK","UNK","1.6","Fold","Increase","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)","ncit:positive","ncit:Qualitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36599",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 14:35:23 -0700","DDI-clinical-trial","evidence-supports","Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.","ncit:positive","ncit:quantitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","P88","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","3","SD","Oral","1","BID","Oral","4","19","55","Percent","Increase","UNKUNUNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/9c4bedb4-2d59-4fcd-aad7-fce988cd96d8.html","2016-02-29 14:20:16 -0700","drug-drug-interaction","evidence-supports","Reduced cytochrome P450 2D6 isozyme activity drugs that inhibit this isozyme (e.g., fluoxetine and paroxetine) and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.","ncit:positive","ncit:Qualitative","thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36284","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 10:50:15 -0800","DDI-clinical-trial","evidence-challenges","Lithium – In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.","ncit:negative","ncit:quantitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","Lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","500","BID","Oral","5","BID","Oral","5","13","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-12-17 18:44:54 -0700","DDI-clinical-trial","evidence-supports","Midazolam (a sensitive CYP 3A4 substrate): A study in patients with schizophrenia showed a less than 50% increase in midazolam total exposure at iloperidone steady state (14 days of oral dosing at up to 10 mg iloperidone twice daily) and no effect on midazolam Cmax. Thus, an interaction between iloperidone and other CYP3A4 substrates is unlikely.","ncit:positive","ncit:quantitative","iloperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","up to 10","midazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","UNK","UNK","Oral","UNK","BID","Oral","14","UNK","UNK","UNK","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.)","ncit:positive","ncit:Qualitative","Quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b33548","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f.html","2016-02-16 16:45:41 -0700","drug-drug-interaction","evidence-supports","Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). and decreased by the prototype CYP3A4 inducers (e..g, phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.).","ncit:positive","ncit:Qualitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction",,"Quetiapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nodeID://b36526",,,,,,,,,,,,,,,,,,,
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 14:46:00 -0700","DDI-clinical-trial","evidence-supports","Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. ","ncit:positive","ncit:quantitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","20","P95","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","3","SD","Oral","1","BID","Oral","21","23","50","Percent","Decrease","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html","2015-11-29 11:47:05 -0800","DDI-clinical-trial","evidence-challenges","Propranolol – The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n = 18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in Cmax and AUC of propranolol, respectively, and a 14% reduction in Cmax for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.","ncit:negative","ncit:quantitative","triazole-dione","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","200","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","40","BID","Oral","5.5","BID","Oral","5.5","18","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/d5051fbc-846b-4946-82df-341fb1216341.html","2016-02-16 13:14:56 -0700","DDI-clinical-trial","evidence-challenges","Administration of intramuscular lorazepam (2 mg) 1 hour after intramuscular olanzapine for injection (5 mg) did not significantly affect the pharmacokinetics of olanzapine, unconjugated lorazepam, or total lorazepam.","ncit:negative","ncit:quantitative","lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","2","olanzapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","5","SD","IV","1","SD","IV","1","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
"http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/43452bf8-76e7-47a9-a5d8-41fe84d061f0.html","2015-11-29 14:38:11 -0700","DDI-clinical-trial","evidence-supports","Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.","ncit:positive","ncit:quantitative","P95","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","3","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","200","SD","Oral","1","BID","Oral","4","19","35","Percent","Increase","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK","UNK"
